Home
About Us
About us
History
Unmet Medical Need
Business Vision And Model
Board Of Directors
Our Team
Contact
BSG005
Invasive Fungal Diseases
BSG005
Pipeline
Publications
Investors
Overview
Events, Presentations and Media
Analyst Coverage
TO2 warrants
Share Information
Ownership
IPO 2021
Filings
Corporate Governance
Corporate Governance
Board Of Directors
Our Team
Press Releases
Rights Issue
Rights Issue 2024
Investor Relations
Rights Issue 2022
Contact
Contact
Imprint
Privacy
The Silent Crisis
“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020
The Silent Crisis
“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020
The Silent Crisis
“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020
The Silent Crisis
“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020
The Silent Crisis
“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020
The Silent Crisis
“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020
The Silent Crisis
“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020
The Silent Crisis
“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020
The Silent Crisis
“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020
The Silent Crisis
“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020
The Silent Crisis
“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020
The Silent Crisis
“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020
The Silent Crisis
“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020
Invasive Fungal Diseases
BSG005
Pipeline
Publications
Pipeline
Phase I in Australia followed by ambitious multi-trial Phase II program leading to broad labeling against invasive fungal infection
Orphan drug status with the FDA provides expedited clinical development and post approval market exclusivity
New formulations in the pipeline
BSG005
Nano Lung
to specifically target the lung
BSG005
Nano Oral
which allows for oral delivery
